Review
Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity

https://doi.org/10.1016/j.amjmed.2018.12.011Get rights and content

Abstract

Patients infected with HIV remain at increased risk of mortality and morbidity from diseases that are preventable with vaccines partly due to the persisting immunopathology that results in impaired responses to vaccination despite virologic suppression. Because data on clinical effectiveness in patients who are immunocompromised remain limited, undervaccination of individuals with HIV poses a major concern. Multiple societies have published recommendations on vaccination in individuals infected with HIV. Many of these recommendations are based on extrapolation of data from clinical trials that usually exclude patients with HIV, although there is a growing body of data from patients infected with HIV as well. In this review, we describe the available literature on vaccine response in the adult patient with HIV as measured by immunogenicity or vaccine efficacy.

Introduction

With the advent of antiretroviral therapy (ART), there has been a substantial reduction in morbidity and mortality associated with HIV infection.1, 2 However, patients with HIV remain at increased risk of mortality and morbidity from vaccine-preventable diseases, such as influenza, partly due to the persisting immunopathology that results in impaired responses to vaccination despite virologic suppression.3, 4

HIV depletes CD4 T lymphocytes, leading to the dysfunction of both cellular and humoral immunity and thereby increases the risk of viral, bacterial, and fungal infections.5 Despite ART, CD4+ T-lymphocytes in individuals infected with HIV remain lower than in a control group without HIV. Moreover, HIV induces B-cell activation and paradoxically causes an inappropriate response to stimulation, which results in suboptimal primary and secondary response to vaccination.6 These changes are similar to the immunosenescence seen in the elderly and most likely is associated with persistent inflammation.7 In the early days of the HIV pandemic, concerns about vaccine safety in patients with HIV were raised because vaccination could activate the immune system and might increase HIV replication and worsen the HIV infection.8, 9 However, this concern has been uncorroborated by numerous studies,10, 11, 12, 13, 14 and now, it is recommended that adult patients infected with HIV receive their age-specific and risk group– based vaccines.

As data on clinical effectiveness in patients who are immunocompromised remains limited, undervaccination of patients with HIV poses a major concern. Multiple societies have published recommendations on vaccination for individuals with HIV.15, 16, 17, 18 Many of these recommendations are based on the extrapolation of data from clinical trials that usually exclude patients with HIV, although there is a growing body of data from patients infected with as well.

In this review, we describe the available literature on vaccine response in the adult patient infected with HIV as measured by immunogenicity or vaccine efficacy (Table).

Section snippets

Haemophilus Influenzae Vaccine

Available Haemophilus influenzae vaccines protect only against H. influenzae type b. Data shows that patients with HIV, particularly those with acquired immunodeficiency syndrome (AIDS), are at increased risk of pneumonia and invasive disease caused by encapsulated H. influenzae bacteria.19, 20, 21, 22 However, vaccines for H. influenzae type b are not routinely recommended for patients infected with HIV17 because most infections are secondary to strains that are not typed.23

Nevertheless,

Measles, Mumps, and Rubella Vaccine

In patients with advanced HIV, severe cases of fatal pneumonitis were reported following measles vaccination.131 When administered, 2 doses of the vaccine are recommended for individuals who lack evidence of measles immunity, were born in 1957 or later, and with no evidence of severe immunodeficiency.

The measles, mumps, and rubella vaccine seems to be safe in patients infected with HIV with a CD4 count >200 cells/mm3.132 Studies looking at the measles, mumps, and rubella vaccine immunogenicity

Conclusion

With the widespread use of ART resulting in better HIV control, clinical vaccine development plans should include patients with HIV and other at-risk populations because they often carry much of the disease burden. An existing large cohort of patients infected with HIV can be used to examine the clinical implications of waning antibody levels thay occur with most vaccines and revisit booster schedules accordingly.

References (139)

  • C Remschmidt et al.

    Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety

    Vaccine

    (2014)
  • FP Kroon et al.

    Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study

    Vaccine

    (2000)
  • AB Nielsen et al.

    Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults

    Vaccine

    (2012)
  • J Lujan-Zilbermann et al.

    Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus

    J Pediatr

    (2012)
  • H Samji et al.

    Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

    PLoS One

    (2013)

  • Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

    Lancet

    (2008)
  • AM Geretti et al.

    Immunization for HIV-positive individuals

    Curr Opin Infect Dis

    (2010)
  • S Kernéis et al.

    Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis

    Clin Infect Dis

    (2014)
  • DL Hanson et al.

    Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group

    Arch Intern Med

    (1995)
  • HC Lane et al.

    Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome

    N Engl J Med

    (1983)
  • V Cobos Jiménez et al.

    T-cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment

    J Infect Dis

    (2016)
  • SK Stanley et al.

    Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1

    N Engl J Med

    (1996)
  • SA Tasker et al.

    Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial

    Ann Intern Med

    (1999)
  • MJ Glesby et al.

    The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study

    J Infect Dis

    (1996)
  • KR Fowke et al.

    Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients

    AIDS

    (1997)
  • A Amendola et al.

    Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users

    J Med Virol

    (2001)
  • LG Rubin et al.

    2013 IDSA clinical practice guideline for vaccination of the immunocompromised host

    Clin Infect Dis

    (2014)
  • JA Aberg et al.

    Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America

    Clin Infect Dis

    (2014)
  • DK Kim et al.

    Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2016

    Ann Intern Med

    (2016)
  • Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment...
  • PA Selwyn et al.

    Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS

    AIDS

    (1988)
  • B Polsky et al.

    Bacterial pneumonia in patients with the acquired immunodeficiency syndrome

    Ann Intern Med

    (1986)
  • R Steinhart et al.

    Invasive Haemophilus influenzae infections in men with HIV infection

    JAMA

    (1992)
  • MM Farley et al.

    Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group

    Ann Intern Med

    (1992)
  • EC Briere et al.

    Prevention and control of Haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP)

    MMWR Recomm Rep

    (2014)
  • MC Steinhoff et al.

    Antibody responses to Haemophilus influenzae type b vaccines in men with human immunodeficiency virus infection

    N Engl J Med

    (1991)
  • H Käyhty et al.

    The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

    J Infect Dis

    (1983)
  • H Peltola et al.

    Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine

    N Engl J Med

    (1984)
  • JB Robbins et al.

    Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies

    Pediatr Res

    (1973)
  • PJ Weiss et al.

    Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine

    J Infect Dis

    (1995)
  • GG Kruglikov et al.

    [Fibroblast differentiation during collagen formation]

    Ontogenez

    (1977)
  • AE Fiore et al.

    Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)

    MMWR Recomm Rep

    (2006)
  • MR Wallace et al.

    Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects

    Clin Infect Dis

    (2004)
  • NJ Bodsworth et al.

    The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up

    AIDS

    (1997)
  • G Hess et al.

    Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men

    J Med Virol

    (1995)
  • NF Crum-Cianflone et al.

    Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults

    J Infect Dis

    (2011)
  • CA Kemper et al.

    Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial

    J Infect Dis

    (2003)
  • GA Neilsen et al.

    Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men

    J Infect Dis

    (1997)
  • D Rimland et al.

    Response to hepatitis A vaccine in HIV patients in the HAART era

    AIDS

    (2005)
  • S Weissman et al.

    Response to hepatitis A vaccine in HIV-positive patients

    J Viral Hepat

    (2006)

    • Cited by (32)

    • Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV

      2023, iScience

    • State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop

      2023, Preventive Medicine Reports

    • Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV

      2021, The Lancet HIV

    • Immunization Strategies to Span the Spectrum of Immunocompromised Adults

      2020, Mayo Clinic Proceedings
      Citation Excerpt :

      In addition to annual influenza vaccination, persons living with HIV should be vaccinated against hepatitis A (if not immune and have risk factors for infection), hepatitis B (if not immune or chronically infected), Tdap, HPV (up to age 26 years), pneumococcus (PCV13 followed by PPSV23), and meningococcus (MCV4).3 Vaccination efficacy, immunogenicity, and vaccine strategies to maximize vaccine responses for adults living with HIV has been recently reviewed.90 Influenza vaccine should be administered during influenza season, regardless of CD4 count or HIV viral load.

    • The immune response to SARS-CoV-2 in people with HIV

      2024, Cellular and Molecular Immunology

    • The Influence of CD4<sup>+</sup> T-Lymphocytes on the Strength of Anti-Diphtheria Immunity in Adult People Living with HIV

      2024, Tuberculosis, Lung Diseases, HIV Infection
    View all citing articles on Scopus

    Funding: None.

    Conflicts of interest: None.

    Authorship: Both authors had access to the data and a role in writing this manuscript.

    View full text
    © 2019 Elsevier Inc. All rights reserved.